Phenotypic Discovery of Neuroprotective Agents by Regulation of Tau Proteostasis via Stress-Responsive Activation of PERK Signaling
- Angew Chem Int Ed Engl. 2021 Jan 25;60(4):1831-1838. doi: 10.1002/anie.202013915.
- 1. CRI Center for Chemical Proteomics, Department of Chemistry, Seoul National University, Seoul, 08826, Korea.
- 2. Department of Biophysics and Chemical Biology, Seoul National University, Seoul, 08826, Korea.
- 3. Department of Physiology, College of Medicine, Hallym University, Chuncheon, 24252, Korea.
- 4. Present address: Department of Chemistry, Soongsil University, Seoul, 06978, Korea.
Tau Protein aggregates are a recognized neuropathological feature in Alzheimer's disease as well as many Other neurodegenerative disorders, known as tauopathies. The development of tau-targeting therapies is therefore extremely important but efficient strategies or protein targets are still unclear. Here, we performed a cell-based phenotypic screening under endoplasmic reticulum (ER) stress conditions and identified a small molecule, SB1617, capable of suppressing abnormal Tau Protein aggregation. By applying label-free target identification technology, we revealed that the transient enhancement of protein kinase-like endoplasmic reticulum kinase (PERK) signaling pathway through the inhibition of stress-responsive SB1617 targets, PDIA3 and DNAJC3, is an effective strategy for regulating proteostasis in tauopathies. The molecular mechanism and the promising efficacy of SB1617 were demonstrated in neuronal cells and a mouse model with traumatic brain injury, a tauopathy known to involve ER stress.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Tau Protein